Smith & Nephew PLC ADR (SNN) News
Filter SNN News Items
SNN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SNN News From Around the Web
Below are the latest news stories about SMITH & NEPHEW PLC that investors may wish to consider to help them evaluate SNN as an investment opportunity.
Are Investors Undervaluing Smith & Nephew plc (LON:SN.) By 39%?Key Insights Smith & Nephew's estimated fair value is UK£16.38 based on 2 Stage Free Cash Flow to Equity Current share... |
Is Smith & Nephew plc (SNN) Among the U.K. Dividend Champions for 2024?We recently compiled a list of the U.K. Dividend Champions List: 2024 Rankings by Yield. In this article, we are going to take a look at where Smith & Nephew plc (NYSE:SNN) stands against the other U.K. dividend champions. In recent years, investors have shown a preference for global stocks, particularly high-growth options like US technology […] |
Is Smith & Nephew plc (SNN) Among the U.K. Dividend Aristocrats for 2024?We recently compiled a list of the U.K. Dividend Aristocrats List: 2024 Rankings by Yield. In this article, we are going to take a look at where Smith & Nephew plc (NYSE:SNN) stands against the other U.K. dividend aristocrats. In recent years, investors have turned away from UK equities, opting instead for global stocks, particularly high-growth […] |
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THASmith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty. |
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip ArthroplastyLatest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and |
SNN Stock Might Rise Following FDA Nod for AETOS StemlessSmith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty. |
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplastySmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless). AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.1 It is designed to maximize metaphyseal fixation and stability with an inlay collar |
3 UK Stocks Estimated To Be Trading At Discounts Of Up To 38.7%The United Kingdom's FTSE 100 index has recently experienced declines, influenced by weak trade data from China that highlights ongoing challenges in global economic recovery. In this environment, identifying undervalued stocks can be particularly appealing as investors seek opportunities in companies trading below their intrinsic value, potentially offering long-term growth despite current market headwinds. |
Smith & Nephew laying off about 150 employees in TennesseeThe job cuts in Memphis, Tennessee, are part of a turnaround plan that has seen the U.K.-based medical device maker shutter four smaller orthopedics facilities outside the U.S. |
Smith & Nephew plc (LON:SN.) is a favorite amongst institutional investors who own 77%Key Insights Given the large stake in the stock by institutions, Smith & Nephew's stock price might be vulnerable to... |